Multidisciplinary

Pregabalin as monotherapy enough to manage fibromyalgia

2 hours ago

Pregabalin, used either alone or in combination with milnacipran, is effective in the treatment of patients with fibromyalgia, and combined therapy does not confer added benefits compared with monotherapy, according to a study.

Old drug, new tricks: Colchicine for chronic coronary disease

Roshini Claire Anthony, 15 hours ago

Low-dose colchicine reduced the risk of multiple cardiovascular (CV) outcomes in patients with chronic coronary disease, according to the LoDoCo2* trial presented at ESC 2020.

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

Pearl Toh, 19 hours ago

Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.

Single-inhaler triple-therapy for COPD: When one is better than more

Audrey Abella, 21 Sep 2020

Single-inhaler triple-therapy (SITT) comprising FF/UMEC/VI* is preferred over dual therapies (DT) or multiple-inhaler (MI) TT for managing COPD**, according to data presented at ERS 2020.

Mepolizumab: Targeting eosinophils in severe asthma with precision medicine

Pearl Toh, 16 Sep 2020

Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.

Inhaled treprostinil ups exercise capacity in pulmonary hypertension

Pearl Toh, 25 Sep 2020

Nivolumab-ipilimumab displays potential in malignant pleural mesothelioma

Roshini Claire Anthony, 24 Sep 2020

For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.

Empagliflozin reduces CV death, HF hospitalization in HFrEF patients

Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

DAPA-CKD heralds a new era for dapagliflozin in kidney disease

Pearl Toh, 23 Sep 2020

Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.

Brensocatib tackles exacerbations in bronchiectasis

Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Masitinib demonstrates potential for severe asthma

Audrey Abella, 22 Sep 2020

The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!